Schlesinger Todd, Rowland Powell Callie
Dermatology and Laser Center of Charleston, Clinical Research Department, Charleston, South Carolina.
J Clin Aesthet Dermatol. 2014 May;7(5):15-8.
Hyaluronic acid sodium salt gel 0.2% is a topical device effective in reducing skin inflammation. Facial seborrheic dermatitis, characterized by erythema and or flaking/scaling in areas of high sebaceous activity, affects up to five percent of the United States population. Despite ongoing study, the cause of the condition is yet unknown, but has been associated with yeast colonization and resultant immune derived inflammation. First-line management typically is with keratolytics, topical steroids, and topical antifungals as well as the targeted immunosuppressant agents pimecrolimus and tacrolimus. The objective of this study was to evaluate the efficacy and safety of a novel topical antiinflammatory containing low molecular weight hyaluronic acid.
Prospective, observational, non-blinded safety and efficacy study in an outpatient setting.
Individuals 18 to 75 years of age with facial seborrheic dermatitis.
Outcome measures included scale, erythema, pruritus, and the provider global assessment, all measured on a five-point scale. Subjects were assessed at baseline, Week 2, Week 4, and Week 8.
Final data with 13 of 17 subjects are presented. Hyaluronic acid sodium salt gel 0.2% was shown through visual grading assessments to improve the provider global assessment by 65.48 percent from baseline to Week 4. Reductions in scale, erythema, and pruritus were 76.9, 64.3, and 50 percent, respectively, at Week 4. At Week 8, the provider global assessment was improved from baseline in 92.3 percent of subjects.
Treatment with topical low molecular weight hyaluronic acid resulted in improvement in the measured endpoints. Final data reveal continued improvement from that seen in the interim data shown previously. Topical low molecular weight hyaluronic acid is another option that may be considered for the treatment of facial seborrheic dermatitis in the adult population. Compliance and tolerance were excellent.
0.2%的透明质酸钠凝胶是一种可有效减轻皮肤炎症的外用产品。面部脂溢性皮炎的特征是皮脂腺活动频繁区域出现红斑和/或脱屑/鳞屑,美国高达5%的人口受其影响。尽管研究仍在进行,但该病的病因尚不清楚,不过已发现其与酵母菌定植以及由此产生的免疫源性炎症有关。一线治疗通常采用角质剥脱剂、外用类固醇、外用抗真菌药以及靶向免疫抑制剂吡美莫司和他克莫司。本研究的目的是评估一种含有低分子量透明质酸的新型外用抗炎药的疗效和安全性。
在门诊环境中进行的前瞻性、观察性、非盲法安全性和疗效研究。
年龄在18至75岁之间的面部脂溢性皮炎患者。
结果指标包括鳞屑、红斑、瘙痒以及医生整体评估,均采用五分制量表进行测量。在基线、第2周、第4周和第8周对受试者进行评估。
呈现了17名受试者中13名的最终数据。通过视觉分级评估显示,0.2%的透明质酸钠凝胶使医生整体评估从基线到第4周提高了65.48%。在第4周时,鳞屑、红斑和瘙痒的减轻率分别为76.9%、64.3%和50%。在第8周时,92.3%的受试者的医生整体评估较基线有所改善。
外用低分子量透明质酸治疗使测量的终点指标得到改善。最终数据显示比之前中期数据中的情况有持续改善。外用低分子量透明质酸是可考虑用于治疗成年人口面部脂溢性皮炎的另一种选择。依从性和耐受性良好。